Ignitas’ portfolio company, OsteoMD, has progressed to the next stage in its market-share winning strategy for its Crespine Gel product. New marketing activities and effort aimed at healthcare providers and consumers are also in production. Ignitas is assisting OsteoMD with financing, visibility strategies, e-marketing, branding, visual identity and corporate communications.

OsteoMD has exclusive distribution rights in Europe, Americas and Africa for Crespine Gel. Crespine Gel is a single injection, hyaluronic acid-based treatment for osteoarthritis. It is CE approved and classified as a medical device rather than a pharmaceutical, making it easier to introduce into new countries. Developed and produced in Germany, Crespine Gel has a unique formulation that makes it superior to all its current competitors. For more information about OsteoMD, contact Runar Eidsaa (runar (a) ignitas.com).